证券代码：688739 证券简称：成大生物 公告编号：2025-043 辽宁成大生物股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开日期时间：2025 年 8 月 28 日 9 点 30 分 召开地点：辽宁省沈阳市浑南区新放街 1 号 公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 28 日 至2025 年 8 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网 投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2025年8月28日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 ...

第五届监事会第十三次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688739 证券简称：成大生物 公告编号：2025-040 辽宁成大生物股份有限公司 一、监事会会议召开情况 辽宁成大生物股份有限公司（以下简称"公司"）第五届监事会第十三次会 议通知于 2025 年 8 月 8 日以电子邮件方式发出，会议于 2025 年 8 月 12 日以现 场与通讯相结合的方式召开并作出决议。应出席会议的监事 3 人，实际出席会议 的监事 3 人，会议由监事会主席郑莹女士主持。本次会议的召集和召开程序符合 《中华人民共和国公司法》（以下简称"《公司法》"）和《辽宁成大生物股份 有限公司章程》（以下简称"《公司章程》"）等相关规定，形成的决议合法有 效。 1 该议案尚需提交公司股东会审议。 具体内容详见公司于同日刊登在上海证券交易所网站（www.sse.com.cn）的 《辽宁成大生物股份有限公司关于取消监事会、修订<公司章程>暨修订、制定 及废止公司部分内部管理制度的公告》（公告编号：2025-042）。 特此 ...

出席会议的董事对本议案进行逐项表决， 表决情况如下： 证券代码：688739 证券简称：成大生物 公告编号：2025-039 辽宁成大生物股份有限公司 第五届董事会第二十一次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 辽宁成大生物股份有限公司（以下简称"公司"）第五届董事会第二十一次会议 通知已于 2025 年 8 月 8 日以电子邮件方式发出，会议于 2025 年 8 月 12 日以现场和 通讯相结合的方式召开并作出决议。公司应出席会议的董事 7 人，实际出席会议的董 事 7 人，会议由董事长李宁先生主持。本次会议的召集、召开和表决情况符合《中华 人民共和国公司法》（以下简称"《公司法》"）等法律法规及《公司章程》的规定， 形成的决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于补选公司董事的议案》 公司董事会于近日收到董事董丙建先生与董事崔建伟先生的书面辞职报告。为完 善公司治理，保证公司董事会的规范运作，根据《公司法》《上海证券交易所科创板 上市公司自律监管指引第 1 ...

Group 1 - The core stock price of Chengda Bio (688739) closed at 28.69 yuan on August 8, 2025, reflecting a 1.06% increase from the previous week's closing price of 28.39 yuan [1] - The highest intraday price reached 28.97 yuan on August 8, while the lowest was 27.93 yuan on August 4 [1] - The current total market capitalization of Chengda Bio is 11.948 billion yuan, ranking 25th out of 50 in the bioproducts sector and 1495th out of 5151 in the A-share market [1] Group 2 - Chengda Bio plans to repurchase shares through centralized bidding, with an estimated amount between 10 million and 20 million yuan [1] - The repurchase plan was first disclosed on June 19, 2025, and the implementation period is from June 19, 2025, to June 18, 2026 [1] - As of July 31, 2025, no shares have been repurchased, and the total repurchase amount is 0 yuan, with the actual repurchase price range being 0 yuan per share [1] - The company intends to use no less than 10 million yuan and no more than 20 million yuan of raised funds for the repurchase, with a maximum repurchase price of 38.00 yuan per share [1] - The company will disclose the progress of the repurchase plan within the first three trading days of each month [1]

Summary of Key Points Core Viewpoint - Chengda Biological Co., Ltd. has announced its share repurchase plan, which is aimed at employee stock ownership plans or equity incentives, but as of July 31, 2025, the company has not yet implemented this plan [1][3]. Trading Information - On August 5, 2025, Chengda Biological's stock closed at 28.58 yuan, with a slight increase of 0.28% - The trading volume was 21,900 shares, resulting in a total transaction value of 62.5655 million yuan - The net inflow of main funds was 2.6507 million yuan, accounting for 4.24% of the total transaction value - Retail investors had a net inflow of 702,900 yuan, representing 1.12% of the total transaction value, while speculative funds saw a net outflow of 3.3536 million yuan, making up 5.36% of the total transaction value [1][3]. Company Announcement - The share repurchase plan was first disclosed on June 19, 2025, with an implementation period from June 19, 2025, to June 18, 2026 - The expected repurchase amount is between 10 million yuan and 20 million yuan - The repurchase price will not exceed 38.00 yuan per share - As of July 31, 2025, the company has not repurchased any shares, with a total repurchase amount of 0 yuan and a shareholding proportion of 0% - The company will disclose the progress of the repurchase plan within the first three trading days of each month during the repurchase period [1].

Group 1 - The core point of the news is the personnel adjustment at Chengda Biological, with the resignation of the former board secretary Cui Jianwei and the appointment of Li Yeji as the new board secretary [1][3] - Cui Jianwei will continue to serve as a director, deputy general manager, and chief financial officer, indicating that his experience in financial and business management will still contribute to the company's strategic development [3] - Li Yeji, born in October 1992, has a strong educational background and extensive experience in investment banking and asset management, which may align with the company's future capital operation needs [3] Group 2 - The personnel change occurs against the backdrop of a significant shift in Chengda Biological's control structure, with the indirect controlling shareholder changing from the Liaoning State-owned Assets Supervision and Administration Commission to a state of no actual controller [3] - The new controlling shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., gained control through board seat advantages, although this change did not directly lead to management turmoil [3] - Market analysis suggests that the new board secretary's investment banking background may be related to the company's future capital operation requirements [3]

证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价116.81%，其 中，收盘价较发行价溢价的有447只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 4443.07%，热景生物、百利天恒、安集科技等紧随其后，分别溢价1105.04%、1102.27%、1087.29%。 最新收盘价较发行价出现折价的有141只，也即是破发。 科创板股最新收盘价较发行价平均溢价116.81%，其中，141股出现破发。 破发幅度最大的是万润新能，最新价较发行价折价78.95%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 其次是ST帕瓦，该股2022年9月19日上市，最新价较发行价折价76.58%，发行价为51.88元，发行市盈率 为93.68倍，行业平均市盈率为29.25倍，公司主要从事新能源电池材料的研发、生产和销售。 成大生物最新价较发行价折价70.99%，天宜新材最新价较发行价折价65.45%，中科微至最新价较发行 价折价61.35%，康希诺最新价较发行价折价60.04%， ...

Core Viewpoint - Chengda Biological announced on August 4 that as of July 31, 2025, the company has not yet implemented its share repurchase plan and will choose to execute the plan based on market conditions [1] Summary by Relevant Categories - **Company Announcement** - Chengda Biological has released a statement regarding its share repurchase plan, indicating that it remains unimplemented as of the specified date [1] - The company plans to assess market conditions before proceeding with the share repurchase [1]

成大生物最新价较发行价折价71.07%，天宜新材最新价较发行价折价66.00%，康希诺最新价较发行价 折价61.65%，中科微至最新价较发行价折价61.65%，金迪克最新价较发行价折价57.21%。（数据宝） 科创板股破发幅度排名 科创板股最新收盘价较发行价平均溢价114.49%，其中，143股出现破发。 证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价114.49%，其 中，收盘价较发行价溢价的有445只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 3686.03%，热景生物、安集科技、百利天恒等紧随其后，分别溢价1090.17%、1085.87%、1079.76%。 最新收盘价较发行价出现折价的有143只，也即是破发。 破发幅度最大的是万润新能，最新价较发行价折价79.04%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 其次是ST帕瓦，该股2022年9月19日上市，最新价较发行价折价76.75%，发行价为51.88元，发行市盈率 为93.68倍，行业平 ...

Core Viewpoint - The collaboration between Chengda Biological and Zhongke Zhidong Taichu aims to establish an "AI + Vaccine Research Joint Laboratory" to enhance vaccine development through AI technology integration [1][3]. Group 1: Collaboration Details - The partnership focuses on four main areas: data integration and analysis platform construction, development of AI tools for vaccine research, establishment of a scientific service platform, and co-building industry influence through academic forums and promotional activities [2][3]. - Chengda Biological will provide research data and application scenarios, while Zhongke Zhidong Taichu will handle AI technology development and platform construction, retaining intellectual property rights for AI tools and models [1][2]. Group 2: Company Profiles - Chengda Biological is the world's largest producer of human rabies vaccines, with a market share that remains the highest globally, having distributed over 450 million doses across more than 30 countries [3]. - Zhongke Zhidong Taichu, a leading AI model company, aims to advance China's general artificial intelligence infrastructure and has developed the "Zhidong Taichu 3.0" model, which competes with international models like GPT-4o [3][4]. Group 3: Strategic Importance - The collaboration is seen as a significant step towards integrating AI technology into vaccine research, potentially leading to enhanced efficiency and innovation in the industry [2][5]. - Guangdong Minying Investment Co., Ltd. played a crucial role in facilitating this partnership, being a major investor in Zhongke Zhidong Taichu and the largest shareholder of Chengda Biological's parent company [5][6].